 |
Video: What is a Stock Split?
|
 |
| Tharimmune, Inc. is a clinical-stage biotechnology company. Co. is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. According to our THAR split history records, Tharimmune has had 2 splits. | |
 |

Tharimmune (THAR) has 2 splits in our THAR split history database. The first split for THAR took place on November 21, 2023. This was a 1 for 25 reverse split, meaning for each 25 shares of THAR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split. THAR's second split took place on May 28, 2024. This was a 1 for 15 reverse split, meaning for each 15 shares of THAR owned pre-split, the shareholder now owned 1 share. For example, a 40 share position pre-split, became a 2.66666666666667 share position following the split.
When a company such as Tharimmune conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the THAR split history from start to finish, an original position size of 1000 shares would have turned into 2.66666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Tharimmune shares, starting with a $10,000 purchase of THAR, presented on a split-history-adjusted basis factoring in the complete THAR split history.

Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
01/13/2022 |
|
| End date: |
12/10/2025 |
|
| Start price/share: |
$1,031.25 |
|
| End price/share: |
$2.69 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.74% |
|
| Average Annual Total Return: |
-78.16% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$26.11 |
|
| Years: |
3.91 |
|
|
 |
| Date |
Ratio |
| 11/21/2023 | 1 for 25 | | 05/28/2024 | 1 for 15 |
|
 |